Just days after debuting on the NASDAQ, Cynapsus Therapeutics announced positive results for its Parkinson's disease drug that pushed the stock up.
The Toronto-based company released data from three early-and mid-stage studies that showed APL-130277 improved symptoms of the disease and helped turn patients from Off to On.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?